SEC Form 10-Q filed by Bio-Techne Corp
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2024 | $85.00 | Buy → Neutral | Citigroup |
| 2/8/2024 | $80.00 | Sector Outperform | Scotiabank |
| 2/2/2024 | $65.00 | Buy → Hold | Stifel |
| 12/7/2023 | $80.00 | Buy | UBS |
| 8/28/2023 | Outperform | William Blair | |
| 1/10/2023 | $90.00 | Underweight → Equal Weight | Wells Fargo |
| 12/14/2022 | $100.00 | Buy | Deutsche Bank |
| 12/12/2022 | $81.25 → $100.00 | Neutral → Buy | Citigroup |
Citigroup downgraded Bio-Techne from Buy to Neutral and set a new price target of $85.00
Scotiabank initiated coverage of Bio-Techne with a rating of Sector Outperform and set a new price target of $80.00
Stifel downgraded Bio-Techne from Buy to Hold and set a new price target of $65.00
SC 13G - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates. Founded in 2020, Leader Life Sciences is a scientific solutions provider dedicated to empowering the research and diagnostic community in the Middle East and North Africa (MENA) region. Serving as a catalyst f
MINNEAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay. The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease.
Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees MINNEAPOLIS, Nov. 14, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia. Asuragen, a Bio-Techne brand, will be exhibiting and showcasing its latest research products for breast cancer monitoring and carrier screening in booth #811. "The Association for Molecular Pathology is a leading voice in the world of clinical molecular testing. We look forward to it
4 analysts have shared their evaluations of Bio-Techne (NASDAQ:TECH) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $85.75, with a high estimate of $95.00 and a low estimate of $81.00. This current average ref
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and announces $85 price target.
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
10-Q - BIO-TECHNE Corp (0000842023) (Filer)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s
MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D
MINNEAPOLIS, Jan. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Shane Bohnen has been appointed Senior Vice President, General Counsel effective March 3, 2023. Mr. Bohnen succeeds Brenda Furlow, who will be retiring from the Company after serving as Executive Vice President and General Counsel for the past nine years. Brenda has been and will continue to provide transition support until her March 3, 2023, retirement and will serve in a consulting capacity for special projects going forward. Mr. Bohnen has over 20 years of experience as a senior legal advisor, including serving as Bio-Techne's Associate General Counsel since 2019. During his tenure at Bio-T
MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2024. First Quarter FY2025 Highlights First quarter organic revenue increased by 4% (5% reported) to $289.5 million. GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago. Delivered adjusted EPS of $0.42 compared to $0.41 one year ago. Continued adoption and utilization across the Diagnostics & Spatial Biology ("DSS"), formerly Diagnostics & Genomics, portfolio led to 14% organic segment growth (14% reported). Continued uptake of our cell and gene therapy workflow solutions, including strong growth in our GMP reagent offeri
MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2024. The quarterly dividend will be payable November 22, 2024, to all common shareholders of record on November 11, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress o
MINNEAPOLIS, Oct. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, October 30, 2024, at 8:00 a.m. CDT to review its first quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: October 30, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13749405 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and refere